Brevan Howard Capital Management Reduces $6M in Ascendis Pharma A/S ($ASND)
Key Points
- Brevan Howard Capital Management changed its Ascendis Pharma A/S ($ASND) stake by 45.71% last quarter, cutting to 26,200 shares worth $6.99 million.
- Wall Street's consensus rating on $ASND is Strong Buy and an average price target of $314.92.
- $ASND last traded around $266.72.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Brevan Howard Capital Management reduced its position in Ascendis Pharma A/S ($ASND) by 45.71% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 26,200 shares of Ascendis Pharma A/S after selling 22,060 shares during the quarter. Brevan Howard Capital Management's holdings in Ascendis Pharma A/S were worth $6.99 million as of its most recent filing.
Ascendis Pharma A/S Stock Up 7.6%
Shares of Ascendis Pharma A/S ($ASND) traded around $266.72 on Saturday, up 7.6% for the day.
Ascendis Pharma A/S Earnings
Analysts Set New Price Targets
About Ascendis Pharma A/S
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Get Ascendis Pharma A/S alerts
New 13F filings, insider trades, and analyst moves on $ASND, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.